Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1‐MMP, MMP‐2 and MMP‐9 in human glioblastomas
Open Access
- 26 June 2003
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 106 (6) , 848-855
Abstract
Vascular endothelial growth factor (VEGF) is the major endothelial mitogen in central nervous system neoplasms and it is expressed in 64–95% of glioblastomas (GBMs). Tumour cells are the main source of VEGF in GBMs whereas VEGF receptors (VEGFR‐1, its soluble form sVEGFR‐1, VEGFR‐2 and neuropilin‐1) are expressed predominantly by endothelial cells. Infiltrating tumour cells and newly‐formed capillaries progress through the extracellular matrix by local proteolysis involving matrix metalloproteinases (MMPs). Recent studies have shown that VEGF expression and bioavailability can be modulated by MMPs. We reported previously that the expression of MT1‐MMP in human breast cancer cells was associated with an enhanced VEGF expression. We used quantitative RT‐PCR, Western blot, gelatin zymography and immunohistochemistry to study the expression of VEGF, VEGFR‐1, VEGFR‐2, sVEGFR‐1, neuropilin‐1, MT1‐MMP, MMP‐2, MMP‐9 and TIMP‐2 in 20 human GBMs and 5 normal brains. The expression of these MMPs was markedly increased in most GBMs with excellent correlation between mRNA and protein levels; activated forms of MMP‐2 and MMP‐9 were present in 8/18 and 7/18 of GBMs. A majority of GBMs (17/20) also expressed high levels of VEGF, as previously reported, with strong correlation between VEGF and MT1‐MMP gene expression levels, and double immunostaining showed that VEGF and MT1‐MMP peptides co‐localize in tumour and endothelial cells. Our results suggest that the interplay between metalloproteinases and VEGF previously described in experimental tumours may also be operative in human GBMs. Because of its dual ability to activate MMP‐2 and to up‐regulate VEGF, MT1‐MMP might be of central importance in the growth of GBMs and represent an interesting target for anti‐cancer treatments.Keywords
Funding Information
- Communauté Française de Belgique (Actions de Recherches Concertées)
- Commission of European Communities
- Fonds de la Recherche Scientifique Médicale
- Fonds National de la Recherche Scientifique (FNRS, Belgium)
- Fédération Belge Contre le Cancer
- Fonds Spéciaux de la Recherche (University of Liège)
- Centre Anticancéreux près l'Université de Liège
- FB Assurances
- Fondation Léon Frédéricq (University of Liège)
- D.G.T.R.E. from the “Région Wallonne”
- Fonds d'Investissements de la Recherche Scientifique (CHU, Liège, Belgium)
- Federal Office for Scientific, Technical and Cultural Affairs (Brussels, Belgium)
This publication has 35 references indexed in Scilit:
- Expression and regulation of neuropilin-1 in human astrocytomasInternational Journal of Cancer, 2000
- VEGF in Brain TumorsJournal of Neuro-Oncology, 2000
- Angiogenesis in cancer and other diseasesNature, 2000
- Vascular Endothelial Growth Factor (VEGF) in Astrocytic Gliomas – A Prognostic Factor?Journal of Neuro-Oncology, 1999
- Expression of vascular endothelial growth factor in human brain tumorsActa Neuropathologica, 1998
- Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in miceProceedings of the National Academy of Sciences, 1998
- Expression and distribution of vascular endothelial growth factor protein in human brain tumorsActa Neuropathologica, 1997
- Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanismsInternational Journal of Cancer, 1994
- Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature, 1992
- Angiogenic FactorsScience, 1987